A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients

E. Cassinerio, A. Roghi, N. Orofino, P. Pedrotti, L. Zanaboni, E. Poggiali, M. Giuditta, D. Consonni, M. D. Cappellini

Research output: Contribution to journalArticlepeer-review

Abstract

Deferasirox (DFX) is an oral iron chelator with established efficacy and safety. We evaluated by T2* cardiovascular magnetic resonance (CMR) the efficacy of DFX in preventing and removing cardiac and liver iron load and cardiac volume changes, along 5 years in adult thalassemia major (TM) patients. Twenty-three TM patients (9 males/14 women, mean age 36 ± 4 years) were included in this study. Repeated CMR was performed to assess myocardial and liver iron load (baseline t0, after 2.5 years t1, after 5 years t2). Myocardial T2* values changed progressively and increased significantly between t0 and t2 (t0: 27.15 ± 9.58 vs t2: 36.64 ± 6.68, p = 0.0001). At baseline evaluation, a cardiac T2* value

Original languageEnglish
Pages (from-to)939-945
Number of pages7
JournalAnnals of Hematology
Volume94
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Keywords

  • Cardiac iron overload
  • Chelation therapy
  • Deferasirox
  • Liver iron overload
  • Thalassemia major

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients'. Together they form a unique fingerprint.

Cite this